Universal Biosensors (UBI) is a medical diagnostics company focused on the research, development and manufacture of diagnostic test systems for point-of-care (POC) professional and home use. UBI's first product is a blood glucose monitoring device that is being commercialised globally by a Johnson & Johnson Company.
UBI's innovative electrochemical sensor platform can also be applied to a range of medical and healthcare applications — research is underway to develop these future opportunities. UBI does not have internal sales & marketing capabilities and will be seeking partners to take future products to market.
The company is listed on the Australian Securities Exchange, under the ticker "UBI", and operates from its R&D and manufacturing facility in Melbourne, Australia.
UBI's core strategy is to:
- Support LifeScan in the development, manufacture and post-market support of the One Touch Verio blood glucose product
- Extend the electrochemical technology platform to a range of other point of care tests
- To develop strategic partnerships with industry leaders to market and distribute UBI's technology.
